SGLT2 Inhibition in Heart Failure: New Updates
Published: 08 February 2023
12m 35sPart 10 Panel Discussion
29m 31sPart 1 Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? John JV McMurray
10m 53sPart 2 SGLT2 Inhibition in the Elderly and Frail Patients Pardeep Jhund
9m 34sPart 3 Gender Differences in Outcomes With SGLT2 Inhibitors Xiaowen “Wendy” Wang
10m 55sPart 4 Efficacy and Safety of SGLT2 Inhibitors in Black Patients Subodh Verma
15m 19sPart 5 Panel Discussion Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund
10m 28sPart 6 SGLT2 Inhibition in Patients With Improved EF Orly Vardeny
13m 27sPart 7 SGLT2 Inhibition With MRAs and ARNis Muthiah Vaduganathan
11m 47sPart 8 Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors? Eileen O’Meara
This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
- To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
- To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
- To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
- To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
- To assess the merit of ejection fraction in heart failure care
- Primary Care Physicians
- Diabetes Educators
More from this programme
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?
SGLT2 Inhibition in the Elderly and Frail Patients
Gender Differences in Outcomes With SGLT2 Inhibitors
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
SGLT2 Inhibition in Patients With Improved EF
SGLT2 Inhibition With MRAs and ARNis
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Does EF Still Matter in HF Management?
Director, Noninvasive Cardiology / Professor
Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction.
He received his AB from Williams College and his MD from Harvard Medical School.